Recent Finacing
Recent Raise
Harmony Biosciences (Plymouth Meeting) develops and intends to commercialize pitolisant, a histamine H3 receptor antagonist/inverse agonist, for narcolepsy (excessive daytime sleepiness and cataplexy) in the U.S.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Harmony Biosciences.
